Evidence map›Paper›PMID 27042342›Full record

ArticleJournal of ophthalmology2016

A Meta-Analysis of Studies Evaluating Visual and Anatomical Outcomes in Patients with Treatment Resistant Neovascular Age-Related Macular Degeneration following Switching to Treatment with Aflibercept.

Sophie Seguin-Greenstein, Sue Lightman, Oren Tomkins-Netzer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of ophthalmology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. A randomized, open-label, multicenter study of switching to brolucizumab with or without a loading dose for patients with suboptimal anatomically controlled neovascular age-related macular degeneration-the FALCON study.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2022
    Trial
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Refractory neovascular age-related macular degeneration: time-dependent changes of central retinal thickness with anti-VEGF treatment.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2021
    Article
  9. Review
  10. Article
  11. Article
  12. The prognostic value of total macular external limiting membrane and ellipsoid zone damage for clinical outcome in treatment-resistant neovascular age-related macular degeneration.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2020
    Article
  13. Article
  14. Article
  15. Newly Identified Peptide, Peptide Lv, Promotes Pathological Angiogenesis.Journal of the American Heart Association · 2019
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sophie Seguin-GreensteinMoorfields Eye Hospital, 162 City Road, London EC1V 2PD, UK; UCL Institute of Ophthalmology, 11-43 Bath Street, London EC1V 9EL, UK.
Sue LightmanMoorfields Eye Hospital, 162 City Road, London EC1V 2PD, UK; UCL Institute of Ophthalmology, 11-43 Bath Street, London EC1V 9EL, UK; Royal Surrey County Hospital, Egerton Road, Guildford, Surrey GU2 7XX, UK.
Oren Tomkins-NetzerMoorfields Eye Hospital, 162 City Road, London EC1V 2PD, UK; UCL Institute of Ophthalmology, 11-43 Bath Street, London EC1V 9EL, UK; Royal Surrey County Hospital, Egerton Road, Guildford, Surrey GU2 7XX, UK; Bnai Zion Medical Center, 47 Golomb Road, 31048 Haifa, Israel.ORCID 0000-0002-1015-1641

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the introduction of aflibercept, eyes with neovascular age-related macular degeneration (AMD) not responding well to injections of ranibizumab or bevacizumab can be switched to treatment with aflibercept. We carried out a meta-analysis to analyze all available evidence of visual and anatomical outcomes of eyes with resistant neovascular AMD switched to aflibercept at six months. Data from seven retrospective and prospective studies looking at change in best corrected visual acuity (BCVA) and central retinal thickness (CRT) were included. Weighted mean difference (WMD) and 95% CI were estimated using the standardized mean change method. The overall results of the meta-analysis showed a small but statistically significant improvement in BCVA six months following treatment switch to aflibercept (WMD 0.142, 95% CI 0.006 to 0.28; p = 0.04), and the effect was more significant in data gathered from prospective studies (WMD 0.407, 95% CI 0.023 to 0.791, p = 0.038). There was a significant improvement in CRT following treatment switch to aflibercept (WMD -0.36, 95% CI -0.485 to -0.235; p < 0.0001). Our meta-analysis indicates that following treatment switch to aflibercept patients may have a significant improvement in CRT with stabilization or even some improvement in their visual acuity.

Identifiers

PMID27042342
PMCPMC4799814

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.